Posted by Emily Leinbach on January 4th, 2021
Originally published on Hunt Scanlon Media on January 4, 2021.
WALTHAM, Mass., January 4, 2021 – Over the past few months, numerous healthcare organizations have turned to executive search firms to find new chief medical officers. In the era of COVID-19 this is likely to be another burgeoning area for executive search firms. The Bowdoin Group recently placed Diego Cadavid as the new chief medical officer of X4 Pharmaceuticals. Dr. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.
“We’re thrilled for Paula and the team at X4,” said Dave Melville, founder and CEO of The Bowdoin Group. “Diego will be a critical team member as they advance their pipeline of innovative medicines for rare diseases. His experience treating patients in the clinic combined with his extensive drug development background brings a patient-focused perspective that’s critical to the X4 mission.”
“We are very pleased to welcome Diego to our team,” said Paula Ragan, president and CEO of X4 Pharmaceuticals. “We believe his strong clinical development expertise, in particular with the advancement of small molecules and biologics for the treatment of rare and immunological diseases, will be invaluable as we continue to advance our ongoing clinical programs, including our Phase 3 trial of mavorixafor in WHIM syndrome and our Phase 1b studies in Waldenström’s macroglobulinemia and severe congenital neutropenia, as well as our preclinical pipeline.”
Dr. Cadavid brings more than 22 years of experience in drug development and academic research to X4, having led multiple programs through all phases of clinical development, including small molecules and biologics for the treatment of rare and immunological diseases. Most recently, he served as senior vice president and head of clinical development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases, including sickle cell disease and beta-thalassemia as well as muscular dystrophies.
Prior to that, Dr. Cadavid held several leadership positions at Biogen, including senior medical director of the multiple sclerosis clinical development group. While at Biogen, he also worked as a consultant at the center for immunology and inflammatory diseases at Massachusetts General Hospital. Dr. Cadavid holds an MD in medicine and surgery from the Pontificia Universidad Javeriana in Bogotá, Colombia and is board-certified and a U.S. licensed clinical neurologist. He completed post-doctoral training in microbiology and immunology at the University of Texas Health Science Center in San Antonio, Texas and a clinical neurology residency at Georgetown University, and completed a fellowship in neuropathology at Armed Forces Institute of Pathology.
“I am very excited to be joining X4 at this time,” said Dr. Cadavid. “I believe the clinical profile demonstrated by mavorixafor to date to be compelling and that this promising small molecule drug candidate has great potential to treat a range of rare genetic immune diseases and cancers. I look forward to leveraging my clinical and scientific expertise to support the continued advancement of mavorixafor through the clinic, while progressing our preclinical programs into the clinic as well.”
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Cambridge, MA, and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Cambridge, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.
About The Bowdoin Group
The Bowdoin Group is an award-winning retained executive search firm that specializes in C-suite leadership and strategic roles, commercial team expansions, and recruitment process outsourcing for a wide range of companies, ranging from venture-backed startups and emerging growth companies building out their C-suites to larger organizations sourcing talent for rapid market expansion. With deep expertise in Life Sciences, Digital Health, Software & Technology, and FinTech, Bowdoin is uniquely situated to solve recruiting challenges and unmet talent needs more than any other search firm across the U.S. due to its cross-functional reach and domain understanding across healthcare and technology. The firm continuously ranks in the top 2% of the recruiting industry in the U.S. and Canada for client and candidate satisfaction as measured by ClearlyRated’s annual NPS survey. The Bowdoin Group is also active in supporting the local entrepreneurial ecosystem as well as several non-profit organizations, including Life Science Cares, NEVCA, Hack.Diversity, and FinTech Sandbox. For more information, visit us at https://www.bowdoingroup.com/ and connect with us on LinkedIn, Twitter, and Facebook.
Head of Marketing